Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Rhea-AI Summary

Dynavax (Nasdaq: DVAX) will report third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. market close. The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET / 1:30 p.m. PT. Investors can access the live webcast via the Investors > Events & Presentations page at https://investors.dynavax.com/events-presentations. A replay will be available for 30 days after the event. Participants must register to dial into the call and are advised to join about 10 minutes early. Contact information for investor/media inquiries is provided.

Business summary: Dynavax is a commercial-stage biopharmaceutical company with two commercial products: HEPLISAV-B vaccine and CpG 1018 adjuvant.

EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2025-financial-results-and-host-conference-call-on-november-5-2025-302591183.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) report third quarter 2025 results?

Dynavax will report Q3 2025 results on Wednesday, November 5, 2025 after U.S. markets close.

What time is the Dynavax (DVAX) conference call and webcast on November 5, 2025?

The conference call and live audio webcast are scheduled for 4:30 p.m. ET / 1:30 p.m. PT on November 5, 2025.

How can investors access the Dynavax (DVAX) webcast for the Q3 2025 results?

Access the live audio webcast via the Investors > Events & Presentations page at https://investors.dynavax.com/events-presentations.

Will there be a replay of the Dynavax (DVAX) Q3 2025 earnings webcast?

Yes. A replay of the webcast will be available for 30 days following the live event.

Do I need to register to join the Dynavax (DVAX) conference call on November 5, 2025?

Yes. Participants must register using the caller registration link to dial into the call.

Who are the investor contacts for Dynavax (DVAX) regarding the Q3 2025 call?

Investor/media contacts listed are Paul Cox (pcox@dynavax.com) and Nicole Arndt (narndt@dynavax.com) with provided phone numbers.